It would also be interesting to ask whether the association of thrombosis/anticoagulation with worse outcome is unique to ROS1‐ and ALK‐rearranged NSCLCs by conducting similar analyses in other molecularly defined subtypes of NSCLC treated with relevant targeted therapies. Here, ALK is linked to non-small cell lung carcinoma.